Yoshizawa, Takahiro
Uchibori, Ken
Araki, Mitsugu http://orcid.org/0000-0002-7810-4905
Matsumoto, Shigeyuki http://orcid.org/0000-0001-9329-6362
Ma, Biao http://orcid.org/0000-0003-0410-4408
Kanada, Ryo
Seto, Yosuke
Oh-hara, Tomoko
Koike, Sumie
Ariyasu, Ryo
Kitazono, Satoru
Ninomiya, Hironori
Takeuchi, Kengo http://orcid.org/0000-0002-1599-5800
Yanagitani, Noriko
Takagi, Satoshi
Kishi, Kazuma
Fujita, Naoya http://orcid.org/0000-0002-9631-9264
Okuno, Yasushi http://orcid.org/0000-0003-3596-4208
Nishio, Makoto
Katayama, Ryohei http://orcid.org/0000-0001-7394-895X
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19H03524, JP20K21554, JP18K15936, JP18K06594, JP17H06327)
Japan Agency for Medical Research and Development (JP20cm0106203h0005, JP20ck0106472h0002)
Uehara Memorial Foundation (NA)
Nippon Foundation (N/A)
Ministry of Education, Culture, Sports, Science and Technology (NA)
FOCUS Establishing Supercomputing Center of Excellence
Article History
Received: 1 October 2020
Accepted: 10 March 2021
First Online: 16 April 2021
Competing interests
: M. Nishio received grants and personal fees Ono Pharmaceutical, grants, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, grants, Taiho Pharmaceutical, AstraZeneca, Boehringer-Ingelheim, MSD, Novartis, Sankyo Healthcare, Taiho Pharmaceutical, Merck Serono, Astellas, outside the submitted work K. Uchibori reports the employment of family member at Daiichi Sankyo. N. Yanagitani is a consultant of Chugai Pharmaceutical. R. Katayama received research funding from Chugai, TAKEDA, Toppan Printing, and Daiichi-Sankyo. K. Kishi received research funding from TAIHO Pharmaceutical, Chugai Pharmaceutical, and ONO Pharmaceutical. N. Fujita received research grants from API corporation and Toppan Printing and consultation fees from Pfizer. The remaining authors declare no competing interest.